arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Jade Biosciences, Inc.

JBIO

$21.95 ▼ -0.30 (-1.35%) at close

7 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Jade Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $688.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -34.2% ↗

FCF / Share $-3.03 ↘

Trailing P/E —

Price / Book 3.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-127.41M

↓ -83.0% —

FCF / Share Free cash flow per share

$-3.03

↓ -21.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-30.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	15.0% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-36.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-12.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-83.0% Weak ↓ Weak Declining Year-over-year change in net income	7.8% Fair ↑ Fair Improving Year-over-year change in net income	-46.6% Weak ↑ Weak Improving Year-over-year change in net income	-124.3% Weak Weak Year-over-year change in net income	-138.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-21.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	-15.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-34.5% Weak Weak Year-over-year change in free cash flow	28.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.20x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-34.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-97.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-74.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	52.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-32.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-92.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-63.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-188.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-38.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-355%)	-91.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-707%)	-69.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-560%)	-40.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-371%)	-13.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-189%)	72.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+380%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-118.52x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-88.44M	$-33.75M	$-23.49M	$-22.40M	$-54.20M	$-4.57M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-3.19	$-2.44	$-2.87	$-2.10	$-1.87	—	—
Free Cash Flow per Share (USD)	$-3.03	$-2.49	$-2.16	$-1.61	$-2.24	—	—
Book Value per Share (USD)	$6.74	$2.64	$3.94	$5.13	$7.06	$-54.90	—
Tangible Book Value per Share (USD)	$6.74	$2.64	$3.94	$5.13	$7.06	$-54.90	—
Basic Weighted Avg Shares (shares)	31.36M	28.58M	26.33M	24.47M	12.29M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$332.28M	$76.29M	$106.59M	$123.71M	$171.78M	$2.90M	—
Total Equity (USD)	$332.52M	$76.43M	$109.46M	$126.74M	$172.42M	$-13.34M	$-3.64M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$26.00K	$282.00K	$96.00K	$68.00K	$15.00K	$1.00K	—
Net Income, GAAP (USD)	$-127.41M	$-69.63M	$-75.52M	$-51.51M	$-22.96M	$-9.61M	—
Operating Cash Flow (USD)	$-94.69M	$-71.20M	$-56.78M	$-39.12M	$-27.40M	$-7.86M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Jade Biosciences, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare JBIO with peers